Allied Market Research
Loading...
Cart
0
New
New Allied Market Research

Rheumatoid Arthritis Drugs Market by Drug Class (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Route of Administration (Oral and Parenteral), and Sales Channel (Prescription-based Drugs, and Over-the-counter Drugs): Global Opportunity Analysis and Industry Forecast, 2020–2027

A03411
Pages: 219
Oct 2020 | 4739 Views
 
Author(s) : Ankita Sonar, Sushant Terdale , Onkar Sumant
Tables: 117
Charts: 44
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Rheumatoid Arthritis Drugs Market

Request Now !

Rheumatoid Arthritis Drugs Market Overview:

The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.

Rheumatoid arthritis is a disease that causes pain and inflammation in joints. It affects individuals of all ages; however, the geriatric population is highly susceptible to develop this disease. The symptoms of rheumatoid arthritis include pain, stiffness, tender, and swelling of joints. Currently, no cure is available for rheumatoid arthritis. However, certain drugs are used to efficiently control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs. 

Rheumatoid-Arthritis-Drugs-Market,-2020-2027

Get more information on this report : Request Sample Pages

Rise in prevalence of rheumatoid arthritis, increase in demand for rheumatoid arthritis drugs, expiration of patents & the entry of biosimilar drugs, surge in geriatric population, increase in adoption of conventional DMARDs, and government initiatives toward spread in awareness for rheumatoid arthritis symptoms are the major factors that drive growth of the rheumatoid arthritis drugs market. In addition, innovations in advanced biologics, rise in healthcare expenditure, improvement in buying power, and access to quality drugs to poor & middle-class families globally are some other factors that contribute toward growth of the market. However, side effects associated with the medication and high costs of biological DMARD therapies are expected to act as the key restraints of the global market. On the contrary, rise in awareness related to early screening and treatment of rheumatoid arthritis is anticipated to offer high growth potential for the rheumatoid arthritis drugs market during the forecast period.

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. According to the Lancet Rheumatology 2020, patients with rheumatoid arthritis who develop COVID-19 infection may be at high risk for developing severe symptoms and additional complications. Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drug, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs during the forecast period.

Rheumatoid Arthritis Drugs Market Segmentation  

The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region. Depending on drug class, the market is categorized into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. By route of administration, it is segregated into oral and parenteral. On the basis of sales channel, it is fragmented into prescription-based drugs and over-the-counter drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Rheumatoid Arthritis Drugs Market
By Drug Class

Your browser does not support the canvas element.

Disease-modifying Anti-rheumatic Drugs segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment review 

Presently, on the basis of drug class, the disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor, and is projected to grow significantly during the forecast period. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost growth of the segment.

Depending on sales channel, the prescription-based drugs segment is the major shareholder in the global rheumatoid arthritis drugs market, owing to advantages offered by prescription-based drugs such as patients gets the correct dosage of the drug during the treatment of rheumatoid arthritis, without causing any side effects, and it prevents the potential scope of drug misuse. However, the OTC drugs segment is expected to exhibit the fastest growth rate during the forecast period, owing to convenience of direct purchase and increase in innovations & developments in OTC drugs.

Rheumatoid Arthritis Drugs Market
By Sales Channel

Your browser does not support the canvas element.

Prescription-Based Drugs segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific rheumatoid arthritis drugs market  

Asia-Pacific presents lucrative opportunities for key players operating in the rheumatoid arthritis drugs market, owing to the presence of large population base susceptible to rheumatoid arthritis, increase in public awareness toward use & benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in adoption of rheumatoid arthritis drugs. Moreover, increase in demand for DMARDs and rise in geriatric population contribute toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high rheumatoid arthritis drugs market share is expected to drive growth of the market in the region.

The key players profiled in this report include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A.

Rheumatoid Arthritis Drugs Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 3.2% during 2019-2026.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the rheumatoid arthritis drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers rheumatoid arthritis drugs market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the rheumatoid arthritis drugs market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global rheumatoid arthritis drugs market growth.

Key Market Segments

By Drug Class

  • Disease-modifying Anti-rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Sales Channel

  • Prescription-based Drugs
  • Over-the-counter Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective44

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Top player positioning, 2019
3.4.Porter’s five force analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Surge in geriatric population across the globe
3.5.1.2.Increase in healthcare expenditure worldwide
3.5.1.3.Rise in prevalence of rheumatoid arthritis across the globe

3.5.2.Restraint

3.5.2.1.Lack of access to treatment of rheumatoid arthritis in underdeveloped countries

3.5.3.Opportunity

3.5.3.1.High growth potential in emerging markets

3.5.4.Impact analysis

3.6.Covid-19 impact analysis on rheumatoid arthritis drugs market

CHAPTER 4:RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.Disease-modifying anti-rheumatic drugs

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Nonsteroidal anti-inflammatory drugs

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Corticosteroids

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

4.5.Uric acid drugs

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country

4.6.Others

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country

CHAPTER 5:RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Oral

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Parenteral

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Prescription-based drugs

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Over-the-counter drugs

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
 7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. rheumatoid arthritis drugs market, by drug class
7.2.2.1.2.U.S. rheumatoid arthritis drugs market, by route of administration
7.2.2.1.3.U.S. rheumatoid arthritis drugs market, by sales channel

7.2.2.2.Canada

7.2.2.2.1.Canada rheumatoid arthritis drugs market, by drug class
7.2.2.2.2.Canada rheumatoid arthritis drugs market, by route of administration
7.2.2.2.3.Canada rheumatoid arthritis drugs market, by sales channel

7.2.2.3.Mexico

7.2.2.3.1.Mexico rheumatoid arthritis drugs market, by drug class
7.2.2.3.2.Mexico rheumatoid arthritis drugs market, by route of administration
7.2.2.3.3.Mexico rheumatoid arthritis drugs market, by sales channel

7.2.3.North America market size and forecast, by drug class
7.2.4.North America market size and forecast, by route of administration
7.2.5.North America market size and forecast, by sales channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany rheumatoid arthritis drugs market, by drug class
7.3.2.1.2.Germany rheumatoid arthritis drugs market, by route of administration
7.3.2.1.3.Germany rheumatoid arthritis drugs market, by sales channel

7.3.2.2.France

7.3.2.2.1.France rheumatoid arthritis drugs market, by drug class
7.3.2.2.2.France rheumatoid arthritis drugs market, by route of administration
7.3.2.2.3.France rheumatoid arthritis drugs market, by sales channel

7.3.2.3.UK

7.3.2.3.1.UK rheumatoid arthritis drugs market, by drug class
7.3.2.3.2.UK rheumatoid arthritis drugs market, by route of administration
7.3.2.3.3.UK rheumatoid arthritis drugs market, by sales channel

7.3.2.4.Italy

7.3.2.4.1.Italy rheumatoid arthritis drugs market, by drug class
7.3.2.4.2.Italy rheumatoid arthritis drugs market, by route of administration
7.3.2.4.3.Italy rheumatoid arthritis drugs market, by sales channel

7.3.2.5.Spain

7.3.2.5.1.Spain rheumatoid arthritis drugs market, by drug class
7.3.2.5.2.Spain rheumatoid arthritis drugs market, by route of administration
7.3.2.5.3.Spain rheumatoid arthritis drugs market, by sales channel

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe rheumatoid arthritis drugs market, by drug class
7.3.2.6.2.Rest of Europe rheumatoid arthritis drugs market, by route of administration
7.3.2.6.3.Rest of Europe rheumatoid arthritis drugs market, by sales channel

7.3.3.Europe market size and forecast, by drug class
7.3.4.Europe market size and forecast, by route of administration
7.3.5.Europe market size and forecast, by sales channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan rheumatoid arthritis drugs market, by drug class
7.4.2.1.2.Japan rheumatoid arthritis drugs market, by route of administration
7.4.2.1.3.Japan rheumatoid arthritis drugs market, by sales channel

7.4.2.2.China

7.4.2.2.1.China rheumatoid arthritis drugs market, by drug class
7.4.2.2.2.China rheumatoid arthritis drugs market, by route of administration
7.4.2.2.3.China rheumatoid arthritis drugs market, by sales channel

7.4.2.3.Australia

7.4.2.3.1.Australia rheumatoid arthritis drugs market, by drug class
7.4.2.3.2.Australia rheumatoid arthritis drugs market, by route of administration
7.4.2.3.3.Australia rheumatoid arthritis drugs market, by sales channel

7.4.2.4.India

7.4.2.4.1.India rheumatoid arthritis drugs market, by drug class
7.4.2.4.2.India rheumatoid arthritis drugs market, by route of administration
7.4.2.4.3.India rheumatoid arthritis drugs market, by sales channel

7.4.2.5.South Korea

7.4.2.5.1.South Korea rheumatoid arthritis drugs market, by drug class
7.4.2.5.2.South Korea rheumatoid arthritis drugs market, by route of administration
7.4.2.5.3.South Korea rheumatoid arthritis drugs market, by sales channel

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific rheumatoid arthritis drugs market, by drug class
7.4.2.6.2.Rest of Asia-Pacific rheumatoid arthritis drugs market, by route of administration
7.4.2.6.3.Rest of Asia-Pacific rheumatoid arthritis drugs market, by sales channel

7.4.3.Asia-Pacific market size and forecast, by drug class
7.4.4.Asia-Pacific market size and forecast, by route of administration
7.4.5.Asia-Pacific market size and forecast, by sales channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil rheumatoid arthritis drugs market, by drug class161
7.5.2.1.2.Brazil rheumatoid arthritis drugs market, by route of administration
7.5.2.1.3.Brazil rheumatoid arthritis drugs market, by sales channel

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia rheumatoid arthritis drugs market, by drug class
7.5.2.2.2.Saudi Arabia rheumatoid arthritis drugs market, by route of administration
7.5.2.2.3.Saudi Arabia rheumatoid arthritis drugs market, by sales channel

7.5.2.3.South Africa

7.5.2.3.1.South Africa rheumatoid arthritis drugs market, by drug class
7.5.2.3.2.South Africa rheumatoid arthritis drugs market, by route of administration
7.5.2.3.3.South Africa rheumatoid arthritis drugs market, by sales channel

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA rheumatoid arthritis drugs market, by drug class
7.5.2.4.2.Rest of LAMEA rheumatoid arthritis drugs market, by route of administration
7.5.2.4.3.Rest of LAMEA rheumatoid arthritis drugs market, by sales channel

7.5.3.LAMEA market size and forecast, by drug class
7.5.4.LAMEA market size and forecast, by route of administration
7.5.5.LAMEA market size and forecast, by sales channel

CHAPTER 8:COMPANY PROFILES

8.1.ABBVIE INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.AMGEN INC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.BRISTOL-MYERS SQUIBB COMPANY

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.ELI LILLY AND COMPANY

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.F. HOFFMANN-LA ROCHE LTD.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.JOHNSON & JOHNSON

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.MERCK & CO., INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.NOVARTIS AG (SANDOZ)

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.PFIZER INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.UCB S.A.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.CORTICOSTEROIDS RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 05.URIC ACID RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.OTHERS RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 08.ORAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.PARENTERAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 11.PRESCRIPTION-BASED RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 12.OVER-THE-COUNTER RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 13.RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 16.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 17.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 18.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 19.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 20.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 21.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 22.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 23.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 24.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 25.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 26.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 27.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 29.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 30.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 31.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 32.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 33.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 34.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 35.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 36.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 37.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 38.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 39.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 40.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 41.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 42.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 43.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 44.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 45.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 46.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 47.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 48.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 49.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 50.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 51.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 52.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 53.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 54.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 55.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 56.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 57.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 58.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 59.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 60.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 61.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 62.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 63.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 64.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 65.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 66.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 67.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 68.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 69.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 70.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 71.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 72.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 73.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 74.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 75.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 76.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 77.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 78.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 79.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 80.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 81.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 82.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 83.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 84.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019–2027
TABLE 85.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027
TABLE 86.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019–2027
TABLE 87.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 88.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 89.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.AMGEN: COMPANY SNAPSHOT
TABLE 91.AMGEN: PRODUCT PORTFOLIO
TABLE 92.BMS: COMPANY SNAPSHOT
TABLE 93.BMS: PRODUCT PORTFOLIO
TABLE 94.LILLY: COMPANY SNAPSHOT
TABLE 95.LILLY: PRODUCT PORTFOLIO
TABLE 96.LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE: OPERATING SEGMENT
TABLE 99.ROCHE: PRODUCT PORTFOLIO
TABLE 100.J&J: COMPANY SNAPSHOT
TABLE 101.J&J: OPERATING SEGMENTS
TABLE 102.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 103.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 104.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 105.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 106.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107.NOVARTIS: COMPANY SNAPSHOT
TABLE 108.NOVARTIS: OPERATING SEGMENT
TABLE 109.NOVARTIS: PRODUCT PORTFOLIO
TABLE 110.PFIZER: COMPANY SNAPSHOT
TABLE 111.PFIZER: OPERATING SEGMENT
TABLE 112.PFIZER: PRODUCT PORTFOLIO
TABLE 113.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.UCB: COMPANY SNAPSHOT
TABLE 115.UCB: OPERATING SEGMENT
TABLE 116.UCB: PRODUCT PORTFOLIO
TABLE 117.UCB: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLAYER POSITIONING, 2019
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
FIGURE 06.HIGH THREAT OF SUBSTITUTES
FIGURE 07.HIGH THREAT OF NEW ENTRANTS
FIGURE 08.MODERATE INTENSITY OF RIVALRY
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY COUNTRY,  2019 & 2027 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CORTICOSTEROIDS RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY,  2019 & 2027 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF URIC ACID RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF OTHER RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF ORAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF PARENTERAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF PRESCRIPTION-BASED RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY,  2019 & 2027 ($MILLION)
FIGURE 19.ABBVIE INC: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.ABBVIE INC.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 21.AMGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.AMGEN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 23.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.BMS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 25.LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 26.LILLY: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 27.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 29.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 30.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 32.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 33.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 38.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 39.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 41.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 42.UCB: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.UCB: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 44.UCB: REVENUE SHARE BY REGION, 2019 (%)

 
 

Rheumatoid arthritis is a chronic inflammatory medical disease in which the body’s immune system attacks its own tissue such as joints. This leads to painful swelling and stiffness in the joints. The medications used for the treatment of rheumatoid arthritis are called anti-rheumatic drugs.

The utilization of rheumatoid arthritis drugs has witnessed a significant growth, owing to surge in incidences of rheumatoid arthritis. The other factors that propel the utilization of different rheumatoid arthritis drugs include increase in geriatric population across the globe, as the medical condition is more predisposed in elderly patients. Conversely, high price of the biological DMARD is a major factor that hinders the growth of the market. Whereas, surge in awareness related to the use of rheumatoid arthritis drugs is expected to present lucrative opportunities for the key players during the forecast period.

North America is expected to remain dominant during the forecast period, due to increase in demand for rheumatoid arthritis drugs, alarming rise in prevalence of rheumatoid arthritis, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to increase in patient awareness toward rheumatoid arthritis treatment.

 

 

 

 

 

 

 

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Rheumatoid Arthritis Drugs market is $57,928.5 million in 2019.

A. The forcast period for Rheumatoid Arthritis Drugs market is 2020 to 2027

A. The market value of Rheumatoid Arthritis Drugs market in 2020 is $52,048.8 million.

A. The base year is 2019 in Rheumatoid Arthritis Drugs market

A. Top companies such as AbbVie Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, and UCB S.A. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Disease-modifying anti-rheumatic drugs segment is the most influencing segment owing to rise in prevalence of rheumatoid arthritis syndrome across the globe, increase in obese & overweight population, launch of therapeutic agents, and favorable reimbursement policies for high cost treatments

A. Rise in incidence of rheumatoid arthritis, increase in demand for DMARDs, and surge in geriatric population across the globe are the key factors that fuel the growth of the global rheumatoid arthritis drugs market. In addition, rise in patient awareness toward availability of various treatments for rheumatoid arthritis, increase in focus of pharmaceutical companies to tap the rare & specialty diseases, and rise in R&D activities and product innovations notably contribute toward the growth of the global market

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 3.9%. This is due to increase in geriatric population, increase in healthcare expenditure and surge in awareness related to the use of rheumatoid arthritis drugs, surge in prevalence of rheumatoid arthritis, surge in adoption of disease-modifying DMARDs, and improvement in healthcare infrastructure.

A. Rheumatoid arthritis is an autoimmune disease that majorly affects joints along with articular tissues and extra-articular organs. It is considered as a systemic disease, as it affects the cardiac and respiratory system

A. Rheumatoid arthritis drugs are used to reduce or prevent joint damage associated with inflammatory conditions of the joints

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Rheumatoid Arthritis Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts